AtriCure Inc (ATRC)

Currency in USD
40.15
-0.74(-1.81%)
Closed·
40.93+0.78(+1.94%)
·
Advertisement
ATRC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
39.8541.16
52 wk Range
25.3643.18
Key Statistics
Prev. Close
40.89
Open
40.75
Day's Range
39.85-41.16
52 wk Range
25.36-43.18
Volume
893.61K
Average Volume (3m)
953.85K
1-Year Change
14.2898%
Book Value / Share
10.2
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATRC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
47.33
Upside
+17.89%
Members' Sentiments
Bearish
Bullish
ProTips
4 analysts have revised their earnings downwards for the upcoming period

AtriCure Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Analyst Ratings

8 Buy
2 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 47.33
(+17.89% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Buy50.00+24.53%55.00Maintain28/07/2026
Citizens
Buy52.00+29.51%-Maintain21/07/2026
Canaccord
Buy55.00+36.99%-Maintain30/06/2026
Canaccord
Buy55.00+36.99%53.00Maintain06/05/2026
Needham
Buy45.00+12.08%-Maintain06/05/2026

AtriCure Inc Earnings Call Summary for Q2/2026

  • AtriCure posted Q2 2026 adjusted EPS of $0.18, beating estimates by $0.19, while revenue rose 12.8% YoY to $153.6M; shares fell 6.4% after-hours.
  • Gross margin improved 220bps to 77.2%; company raised full-year adjusted EBITDA guidance to $85M-$89M and expects positive net income for 2026.
  • Pain management revenue surged 27% driven by CryoSphere MAX adoption; minimally invasive ablation remained pressured amid market shift to PFA catheters.
  • Full-year revenue guidance set at $602M-$610M (12.5%-14% growth); Q3 expected to decline 1%-2% sequentially before Q4 rebound.
  • BoxX-NoAF trial enrollment on track to complete by end-2026 with data expected H1 2027; PMA filing anticipated alongside May 2027 medical meeting presentation.
Last Updated: 23/07/2026, 22:32
Read Full Transcript

Earnings

Latest Release
23/07/2026
EPS / Forecast
0.18 / -0.01
Revenue / Forecast
153.6M / 151.84M
EPS Revisions
Last 90 days

Compare ATRC to Peers and Sector

Metrics to compare
ATRC
Peers
Sector
Relationship
P/E Ratio
193.5x10.8x−0.3x
PEG Ratio
1.550.110.00
Price/Book
4.0x2.1x2.6x
Price / LTM Sales
3.6x2.1x2.9x
Upside (Analyst Target)
22.3%38.1%56.7%
Fair Value Upside
Unlock22.8%10.2%Unlock

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula’s to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
25.46M50.27%1.04B
Other Institutional Investors
26.31M49.73%1.08B
Public Companies & Retail Investors
0.000.00%0.00
Total
51.77M100.00%2.12B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.7.98%4,042,681165,305
Wellington Management Group LLP6.68%3,382,555138,313

People Also Watch

68.25
STC
-2.83%
63.03
CATY
-0.33%
331.35
WINA
-0.86%
23.50
ATNI
-0.97%
41.19
FSTR
+2.26%

FAQ

What Is the AtriCure (NASDAQ: ATRC) Share Price Today?

The AtriCure stock price today is 40.15 USD.

What Stock Exchange Does AtriCure (ATRC) Trade On?

AtriCure is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for AtriCure?

The stock symbol (also called a 'ticker') for AtriCure is "ATRC."

What Is the Current AtriCure Market Capitalisation?

As of today, AtriCure (NASDAQ: ATRC) market cap is 2.03B USD.

What Is AtriCure's (ATRC) Earnings Per Share (TTM)?

The AtriCure EPS is currently 0.22 (Trailing Twelve Months).

When Is the Next AtriCure Earnings Date?

AtriCure's next earnings report will be released on 04/11/2026.

Is ATRC a Buy or Sell From a Technical Analyst Perspective?

Based on today's AtriCure moving averages and other technical indicators, the daily buy/sell signal for ATRC stock is Strong Buy.

How Many Times Has AtriCure Stock Split?

AtriCure has split 0 times. (See the ATRC stock split history page for full effective split date and price information.)

How Many Employees Does AtriCure Have?

AtriCure has 1350 employees, based on their latest Companies House report.

What is the current trading status of AtriCure (NASDAQ: ATRC)?

As of 30/07/2026, AtriCure (ATRC) is trading at a share price of 40.15 USD, with a previous close of 40.89 USD. The stock has fluctuated within a day range of 39.85 USD to 41.16 USD, while its 52-week range spans from 25.36 USD to 43.18 USD.

What Is AtriCure (ATRC) Price Target According to Analysts?

The average 12-month price target for AtriCure is 47.33 USD, with a high estimate of 55 USD and a low estimate of 36 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +17.89% Upside potential.

What Is the ATRC Premarket Price?

ATRC's last pre-market stock price is 40.81 USD. The pre-market share volume is 180.00, and the stock has decreased by -0.08, or -0.20%.

What Is the ATRC After Hours Price?

ATRC's last after hours stock price is 40.93 USD, the stock has decreased by 0.78, or 1.94%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.